Derigs, Patrick http://orcid.org/0000-0002-4670-8851
Radujkovic, Aleksandar
Schubert, Maria-Luisa
Schnitzler, Paul
Schöning, Tilman
Müller-Tidow, Carsten
Hegenbart, Ute
Schönland, Stefan O.
Luft, Thomas
Dreger, Peter
Schmitt, Michael
Funding for this research was provided by:
Department of Internal Medicine V (Hematology/Oncology/Rheumatology) of the Heidelberg University Hospital, Heidelberg, Germany
Article History
Received: 24 September 2020
Accepted: 23 November 2020
First Online: 3 December 2020
Compliance with ethical standards
:
: P.De. received an honorarium for a scientific presentation by MSD.M.S. received funding for collaborative research from Apogenix, Hexal and Novartis, travel grants from Hexal and Kite, financial support for educational activities and conferences from bluebird bio, Kite and Novartis, is an advisory board member for MSD and (co-)PI of clinical trials of MSD, GSK, Kite and BMS, as well as co-founder and shareholder of TolerogenixX Ltd.P.Dr.: consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser.All other authors report no potential conflicts of interest.
: The local ethics committee of the University Hospital Heidelberg had approved the sample and data collection and analysis (reference number 120/2002). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Written informed consent for data analysis according to the Declaration of Helsinki was obtained from all patients.
: All patients signed informed consent regarding publishing their data.